Clinical trial · Observational
Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Prospective Multicenter Clinical Trial With Multimodality MR Imaging
NCT03102203CI-TRIAL-00026794unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Ktrans
- timeFrame
- baseline
- description
- The volume transfer constant in dynamic contrast-enhanced MR Imaging
- measure
- Ktrans
- timeFrame
- 3 months
- description
- The volume transfer constant in dynamic contrast-enhanced MR Imaging
- measure
- Ktrans
- timeFrame
- 10 months
- description
- The volume transfer constant in dynamic contrast-enhanced MR Imaging
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. Written informed consent is obtained. Exclusion Criteria: 1. Patients not suitable for enhanced MRI scanning of patients; 2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning.
References
Publications (0)
Data not yet available
No reference posted for this study.